Ibudilast in relapsing-remitting multiple sclerosis
A neuroprotectant?
Abstract
Background: Ibudilast is a phosphodiesterase inhibitor influencing inflammation and neurodegeneration in multiple sclerosis (MS). This study evaluated the safety, tolerability, and effects on MRI parameters of 2 different doses of ibudilast in relapsing forms of MS.
Methods: In this multicenter, double-blind, phase 2 trial, patients with relapsing MS and gadolinium-enhancing lesions were randomly assigned 1:1:1 to receive 30 or 60 mg ibudilast or placebo every day for 12 months. The primary endpoint was the cumulative number of newly active lesions on bimonthly brain MRI over 12 months. Secondary endpoints included relapse rate, change in Expanded Disability Status Scale (EDSS) score, T2-hyperintense and T1-hypointense lesion volumes, and percent brain volume change (PBVC).
Results: A total of 297 patients were randomized in 19 centers. During the first 12 months, the mean number of active lesions and relapse rate did not differ between treatment arms. A reduction in PBVC (p = 0.04) was found in the 60-mg group (0.8%) compared with placebo (1.2%). Post hoc analysis showed a reduction in the proportion active lesions that evolved into persistent black holes for the 60-mg (0.14; p = 0.004) and 30-mg (0.17; p = 0.036) groups compared with the placebo group (0.24). Over 2 years, there were fewer patients (p = 0.026) with confirmed progression on the EDSS. Treatment with ibudilast was generally safe and well tolerated.
Conclusion: Ibudilast showed no beneficial effect on the rate of newly active lesions and relapses. However, preliminary evidence suggests that ibudilast seems to act in a neuroprotective fashion as measured by 2 independent MRI outcomes, with a possible beneficial clinical effect on disability progression.
Classification of evidence: This interventional study provides Class III evidence on the effect of ibudilast on disease activity.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
REFERENCES
1.
Gibson LC, Hastings SF, McPhee I, et al. The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 2006;538:39–42.
2.
Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFα production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 1999;837:203–212.
3.
Mizuno T, Kurotani T, Komatsu Y, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004;46:404–411.
4.
Armstead WM, Mirro R, Leffler CW, Busija DW. The role of prostanoids in the mediation of responses to KC-404, a novel cerebrovasodilator. J Pharmacol Exp Ther 1988;244:138–143.
5.
Kawasaki A, Hoshino K, Osaki R, Mizushima Y, Yano S. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 1992;29:245–252.
6.
Tominaga Y, Nakamura Y, Tsuji K, Shibata T, Kataoka K. Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons. Clin Exp Pharmacol Physiol 1996;23:519–523.
7.
Wakita H, Tomimoto H, Akiguchi I, et al. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res 2003;992:53–59.
8.
Takuma K, Lee E, Enomoto R, Mori K, Baba A, Matsuda T. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br J Pharmacol 2001;133:841–848.
9.
Kagitani-Shimono K, Mohri I, Fujitani Y, et al. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation 2005;2:10.
10.
Fujimoto T, Sakoda S, Fujimura H, Yanagihara T. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999;95:35–42.
11.
Sommer N, Martin R, McFarland HF, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 1997;79:54–61.
12.
Feng J, Misu T, Fujihara K, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004;10:494–498.
13.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
14.
Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1955;5:580–583.
15.
Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997;49:1682–1688.
16.
Yoshikawa M, Suzumura A, Tamaru T, Takayanagi T, Sawada M. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult Scler 1999;5:126–133.
17.
Paintlia AS, Paintlia MK, Singh I, Singh AK. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 2008;214:168–180.
18.
Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2009;57:182–193.
19.
Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008;71:1390–1395.
Information & Authors
Information
Published In
Copyright
© 2010.
Publication History
Published online: March 3, 2010
Published in print: March 30, 2010
Notes
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?, Current Neuropharmacology, 22, 8, (1286-1326), (2024).https://doi.org/10.2174/1570159X22666240124114126
- Macrophage migration inhibitory factor as a therapeutic target in neuro-oncology: A review, Neuro-Oncology Advances, 6, 1, (2024).https://doi.org/10.1093/noajnl/vdae142
- Diffusion basis spectrum imaging and diffusion tensor imaging predict persistent black hole formation in multiple sclerosis, Multiple Sclerosis and Related Disorders, 84, (105494), (2024).https://doi.org/10.1016/j.msard.2024.105494
- Drug repurposing for neurodegenerative diseases, Clinical Application of Repurposed Drugs, (249-319), (2024).https://doi.org/10.1016/bs.pmbts.2024.03.035
- Neuroprotective Action of Polyphenols and Phenolic Compounds: An Overview, Biosciences Biotechnology Research Asia, 20, 3, (793-816), (2023).https://doi.org/10.13005/bbra/3132
- The effect of ibudilast on thalamic volume in progressive multiple sclerosis, Multiple Sclerosis Journal, 29, 14, (1819-1830), (2023).https://doi.org/10.1177/13524585231204710
- Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis, Multiple Sclerosis Journal, 29, 10, (1257-1265), (2023).https://doi.org/10.1177/13524585231187289
- Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model, International Journal of Pharmaceutics, 638, (122936), (2023).https://doi.org/10.1016/j.ijpharm.2023.122936
- Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders, Autoimmunity Reviews, 22, 5, (103312), (2023).https://doi.org/10.1016/j.autrev.2023.103312
- Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence, Molecules, 27, 23, (8448), (2022).https://doi.org/10.3390/molecules27238448
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.